Showing results (41-50 of 538) with videos related to
Sort By:
Pageof 54
Cancers|September 19, 2020
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized TrialsFrancesco Facchinetti, Massimo Di Maio, Marcello TiseoEuropean Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic reviewClizia Zichi, Chiara Paratore, Piera Gargiulo, et al.The Lancet. Oncology|May 7, 2003
Statistical design in phase II clinical trials and its application in breast cancerFrancesco Perrone, Massimo Di Maio, Ermelinda De Maio, et al.Journal of Cancer Policy|April 23, 2025
Press releases of industry-sponsored clinical trials in oncology: Characteristics, timing and financial impactAnna Amela Valsecchi, Cecilia Conte, Nicola Maria Fiore, et al.Analytical Cellular Pathology (Amsterdam)|January 13, 2017
Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based ChemotherapyErnesta Cavalcanti, Vittoria Barchiesi, Dionigio Cerasuolo, et al.The Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.Expert Review of Respiratory Medicine|February 3, 2017
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancerAntonio Rossi, Anna La Salvia, Massimo Di MaioCancer Management and Research|June 18, 2020
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The EvidenceEmmanuele De Luca, Donatella Marino, Massimo Di MaioTranslational Lung Cancer Research|March 10, 2016
Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancerMassimo Di Maio, Paolo Bironzo, Giorgio Vittorio ScagliottiPageof 54